Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675301 | 1.00 | TP53 (0.33) | TP53KDM4EGAAKMT2AHPGD | |
| SCHEMBL6649637 | 0.81 | CTSC (0.40) | TP53HPGDCTSBCTSS | |
| SCHEMBL6062814 | 0.81 | CTSC (0.40) | TP53HPGDCTSBCTSS | |
| SCHEMBL6651832 | 0.78 | CTSS (0.40) | KMT2AHPGDCTSBCTSS | |
| SCHEMBL6629347 | 0.78 | CTSS (0.40) | KMT2AHPGDCTSBCTSS | |
| SCHEMBL6062755 | 0.73 | HPGD (0.39) | KMT2AHPGDCTSBCTSS | |
| SCHEMBL6629837 | 0.73 | HPGD (0.39) | KMT2AHPGDCTSBCTSS | |
| SCHEMBL6630248 | 0.73 | HPGD (0.42) | KMT2AHPGD | |
| SCHEMBL6630252 | 0.73 | HPGD (0.42) | KMT2AHPGD | |
| SCHEMBL1556740 | 0.73 | CTSS (0.65) | HPGDCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | claimed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | TP53 319/4885KDM4E 4386/4885GAA 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.